# Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis

> **NCT00621400** · PHASE1,PHASE2 · COMPLETED · sponsor: **Nantes University Hospital** · enrollment: 27 (actual)

## Conditions studied

- Amyloidosis

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Melphalan
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT00621400
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2011-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00621400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00621400, "Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00621400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*